abstract |
The present disclosure relates to certain combinations for the treatment of cancer in a subject, comprising one or more inhibitors of Tyro3, Axl, Mer, or c-Met, together with one or more compounds that are inhibitors of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). |